title: Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.
abstract: Helicobacter pylori (HP) eradication therapy is a useful treatment for idiopathic thrombocytopenic purpura (ITP). Some investigators have also reported the effects of proton pump inhibitor (PPI) monotherapy on ITP. We performed a randomized study of HP eradication therapy and PPI monotherapy on ITP. Four of nine patients achieved complete remission (CR), two of nine achieved partial remission (PR) in HP eradication therapy, three of eight achieved CR, and two of eight achieved PR in PPI monotherapy. No significant differences were observed in the CR + PR of these patients between HP eradication therapy and PPI monotherapy. As for cost comparisons, HP eradication therapy is cheaper than PPI monotherapy, but it is less effective.
authors.affiliation: Department of Internal Medicine, Hakodate Municipal Hospital, 1-10-1 Minato-Cho, Hakodate, 041-8680, Japan. rtsutsu@nyc.odn.ne.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tsutsumi
authors.forename: Hiroe
authors.initials: H
authors.lastname: Kanamori
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yamato
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ehira
authors.forename: Takahito
authors.initials: T
authors.lastname: Kawamura
authors.forename: Shintaro
authors.initials: S
authors.lastname: Umehara
authors.forename: Akio
authors.initials: A
authors.lastname: Mori
authors.forename: Shinji
authors.initials: S
authors.lastname: Obara
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Ogura
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
authors.forename: Nobuo
authors.initials: N
authors.lastname: Masauzi
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage* / Q000191:economics; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000191:economics; D017291:Clarithromycin / Q000008:administration & dosage* / Q000191:economics; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D054328:Proton Pump Inhibitors; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000191:economics / Q000201:enzymology; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole